SCHEMBL3859996

SCHEMBL3859996

O=C(Nc1ccccn1)c1cccc(-c2cccs2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.60
NPC1 O15118 9/20 0.52
RAB9A P51151 8/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
TP53 P04637 2/20 0.52
NFKB1 P19838 2/20 0.52
NFKB2 Q00653 2/20 0.52
RELA Q04206 2/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 2/20 0.50
ALOX15 P16050 1/20 0.50
GRM5 P41594 3/20 0.48
ESR1 P03372 1/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3862923 0.80 CNR2 (0.79) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3866119 0.76 CNR2 (0.84) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL9384187 0.76 NPC1 (0.72) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL16996703 0.76 NPC1 (0.62) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL9081166 0.75 KDM4E (0.61) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL14152323 0.75 CNR2 (1.00) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3859292 0.74 GRM5 (0.65) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL31277543 0.74 GRM5 (0.65) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3870512 0.74 GRM5 (0.74) CNR2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1379792 0.74 ALDH1A1 (0.69) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1715867-A4 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2009-04-15 EP disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
EP-1715867-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-11-02 EP disclosed
WO-2005079802-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-09-01 WO disclosed
WO-2005079802-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GABRA5 CNR2 92/4885NPC1 3248/4885RAB9A 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.